531551 Sigma-AldrichPKR/PERK Activator, DHBDC - CAS 101068-35-3 - Calbiochem
A cell permeable dual activator of protein kinase R (PKR) and protein kinase R like kinase (PERK). Induces the phosphorylation of IκBα and thereby activates NF-κB pathway.
More>> A cell permeable dual activator of protein kinase R (PKR) and protein kinase R like kinase (PERK). Induces the phosphorylation of IκBα and thereby activates NF-κB pathway. Less<<Synonyms: Protein Kinase R (PKR) Activator, Protein Kinase R Like Kinase (PERK) Activator
Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
CAS # | Empirical Formula |
---|---|
101068-35-3 | C₁₇H₁₂O₆ |
Products
Catalogue Number | Packaging | Qty/Pack | |
---|---|---|---|
5.31551.0001 | Glass bottle | 10 mg |
References | |
---|---|
References | Bai, H., et al. 2013. ChemBioChem 14, 1255. |
Product Information | |
---|---|
CAS number | 101068-35-3 |
Form | White to pink powder |
Hill Formula | C₁₇H₁₂O₆ |
Chemical formula | C₁₇H₁₂O₆ |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | PKR and PERK |
Primary Target IC<sub>50</sub> | ~ 10 µ |
Purity | ≥98% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
5.31551.0001 | 04055977260373 |
Documentation
PKR/PERK Activator, DHBDC - CAS 101068-35-3 - Calbiochem SDS
Title |
---|
References
Reference overview |
---|
Bai, H., et al. 2013. ChemBioChem 14, 1255. |
Brochure
Title |
---|
NPI Flyer- Epigenetics and Nuclear Function Feature |
New Products - Antibodies, Small Molecule, Inhibitors |
Technical Info
Title |
---|
White Paper: Further considerations of antibody validation and usage. |